Patient characteristics of hepatitis E–confirmed patients (n = 8)
| Patient . | Sex . | Age at alloHSCT, years . | Diagnosis . | Stem cell source . | Alive at EOF . | GVHD . | Initial diagnosis . | At time of alloHSCT . | HEV gt . | Time from alloHSCT to infection, months . | Duration of infection, months . | Median (range) ALT levels during infection, U/L* . | Immunosuppression at time of infection . | Hepatic fibrosis in liver histology . | No. of blood products received within 3 months of infection . | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HEV RNA . | IgG status . | |||||||||||||||
| A | M | 44 | AML | UCB | No | Acute grades II-IV Chronic extensive | GVHD | − | − | 3 | 2.7 | 12.5† | 73 (24-577) | Cciclosporin, prednisone, mycophenolate | N/A | 21 |
| B | F | 54 | NHL | MUD | Yes | Acute grades II-IV Chronic limited | GVHD | − | − | 3 | 8.4 | 42.4 | 207 (31-1507) | Ciclosporin | F3 | 0 |
| C | F | 59 | MDS | MUD | Yes | Acute grades II-IV Chronic extensive | GVHD | − | − | 3 | 3.4 | 6.3 | 72 (36-215) | Ciclosporin, mycophenolate | N/A | 48 |
| D | M | 43 | CLL | MUD | No | None | DILI | − | + | 3 | 14.0 | 1.6† | 66 (15-309) | Alemtuzumab | N/A | 3 |
| E | M | 66 | AML | MUD | No | Acute grades II-IV | DILI | − | + | 3 | 5.8 | 1.7† | 39 (19-268) | Ciclosporin, prednisone, mycophenolate | N/A | 35 |
| F | M | 58 | NHL | MUD | Yes | Acute grades II-IV Chronic extensive | GVHD | − | + | 3 | 18.3 | 11.3 | 208 (25-1130) | Sirolimus, prednisone | F1 | 0 |
| G | F | 39 | SAA | UCB | No | Acute grades II-IV | DILI | + | − | 3 | 0 | 6.5† | 70 (12-213) | Ciclosporin, mycophenol acid | F0 | 21 |
| H | M | 59 | AML | UCB | Yes | None | GVHD | + | − | 3 | −2.0 | 2.1 and 4.9 | 27 (10-550) | None | N/A | 50 |
| Patient . | Sex . | Age at alloHSCT, years . | Diagnosis . | Stem cell source . | Alive at EOF . | GVHD . | Initial diagnosis . | At time of alloHSCT . | HEV gt . | Time from alloHSCT to infection, months . | Duration of infection, months . | Median (range) ALT levels during infection, U/L* . | Immunosuppression at time of infection . | Hepatic fibrosis in liver histology . | No. of blood products received within 3 months of infection . | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HEV RNA . | IgG status . | |||||||||||||||
| A | M | 44 | AML | UCB | No | Acute grades II-IV Chronic extensive | GVHD | − | − | 3 | 2.7 | 12.5† | 73 (24-577) | Cciclosporin, prednisone, mycophenolate | N/A | 21 |
| B | F | 54 | NHL | MUD | Yes | Acute grades II-IV Chronic limited | GVHD | − | − | 3 | 8.4 | 42.4 | 207 (31-1507) | Ciclosporin | F3 | 0 |
| C | F | 59 | MDS | MUD | Yes | Acute grades II-IV Chronic extensive | GVHD | − | − | 3 | 3.4 | 6.3 | 72 (36-215) | Ciclosporin, mycophenolate | N/A | 48 |
| D | M | 43 | CLL | MUD | No | None | DILI | − | + | 3 | 14.0 | 1.6† | 66 (15-309) | Alemtuzumab | N/A | 3 |
| E | M | 66 | AML | MUD | No | Acute grades II-IV | DILI | − | + | 3 | 5.8 | 1.7† | 39 (19-268) | Ciclosporin, prednisone, mycophenolate | N/A | 35 |
| F | M | 58 | NHL | MUD | Yes | Acute grades II-IV Chronic extensive | GVHD | − | + | 3 | 18.3 | 11.3 | 208 (25-1130) | Sirolimus, prednisone | F1 | 0 |
| G | F | 39 | SAA | UCB | No | Acute grades II-IV | DILI | + | − | 3 | 0 | 6.5† | 70 (12-213) | Ciclosporin, mycophenol acid | F0 | 21 |
| H | M | 59 | AML | UCB | Yes | None | GVHD | + | − | 3 | −2.0 | 2.1 and 4.9 | 27 (10-550) | None | N/A | 50 |
+, positive; −, negative; AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; DILI, drug-induced liver injury; EOF, end of follow-up; F, female; gt, genotype; GVHD, graft versus host disease; M, male; MDS, myelodysplastic syndrome; MUD, matched unrelated donor; N/A, not available; NHL, non-Hodgkin's lymphoma; SAA, severe aplastic anemia; UCB, umbilical cord blood.
ALT upper limited of normal, male = 44 U/L or female = 33 U/L.
Patient died having an HEV viremia.